MX375724B - Compuestos y métodos para la inhibición de jak. - Google Patents
Compuestos y métodos para la inhibición de jak.Info
- Publication number
- MX375724B MX375724B MX2018003590A MX2018003590A MX375724B MX 375724 B MX375724 B MX 375724B MX 2018003590 A MX2018003590 A MX 2018003590A MX 2018003590 A MX2018003590 A MX 2018003590A MX 375724 B MX375724 B MX 375724B
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- sub
- methyl
- compounds
- ethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000005764 inhibitory process Effects 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen compuestos de fórmula (I), composiciones farmacéuticas que comprenden tales compuestos y métodos/usos para utilizar los mismos, por ejemplo, para tratar un trastorno relacionado con JAK, tal como cáncer, caquexia por cáncer o un trastorno inmune: (ver Fórmula) donde R1 es metilo o etilo; R2 se selecciona de metilo, etilo, metoxi y etoxi; R3 se selecciona de hidrógeno, cloro, flúor, bromo y metilo; R4 se selecciona de metilo, etilo y-CH2OCH3; R5 y R6 son cada uno individualmente metilo o hidrógeno; y R7 se selecciona de metilo, etilo,-(CH2)2OH y -(CH2)2OCH3, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562232629P | 2015-09-25 | 2015-09-25 | |
| PCT/EP2016/072616 WO2017050938A1 (en) | 2015-09-25 | 2016-09-22 | Compounds and methods for inhibiting jak |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018003590A MX2018003590A (es) | 2018-11-29 |
| MX375724B true MX375724B (es) | 2025-03-06 |
Family
ID=56979589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003590A MX375724B (es) | 2015-09-25 | 2016-09-22 | Compuestos y métodos para la inhibición de jak. |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US9714236B2 (es) |
| EP (2) | EP4219482A1 (es) |
| JP (1) | JP6767491B2 (es) |
| KR (2) | KR20250035597A (es) |
| CN (4) | CN111606893B (es) |
| AR (1) | AR106138A1 (es) |
| AU (1) | AU2016328764B2 (es) |
| BR (1) | BR112018005833B1 (es) |
| CA (1) | CA2995430C (es) |
| DK (1) | DK3353168T3 (es) |
| ES (1) | ES2956642T3 (es) |
| MX (1) | MX375724B (es) |
| PT (1) | PT3353168T (es) |
| RU (1) | RU2760359C2 (es) |
| TW (1) | TWI740843B (es) |
| WO (1) | WO2017050938A1 (es) |
| ZA (1) | ZA201800782B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111606893B (zh) * | 2015-09-25 | 2021-05-04 | 迪哲(江苏)医药股份有限公司 | 用于抑制jak的化合物和方法 |
| CN109311858B (zh) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | Egfr抑制剂化合物 |
| SMT202300051T1 (it) * | 2017-01-17 | 2023-03-17 | Astrazeneca Ab | Inibitori selettivi di jak1 |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| CA3105585A1 (en) | 2018-07-18 | 2020-01-23 | Astrazeneca Ab | A xinafoate salt of a jak inhibiting compound |
| EP3854793A4 (en) | 2018-09-21 | 2022-06-01 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY |
| KR102195348B1 (ko) * | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| BR112021020964A2 (pt) * | 2019-04-19 | 2021-12-14 | Dizal Jiangsu Pharmaceutical Co Ltd | Inibidor seletivo de quinase jak1 |
| CN110627775B (zh) * | 2019-10-24 | 2026-01-30 | 特科罗生物科技(成都)有限公司 | 一种小分子化合物 |
| CN111961037B (zh) * | 2020-09-17 | 2021-09-21 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的药物化合物 |
| JP7613778B2 (ja) * | 2020-11-26 | 2025-01-15 | 科輝智薬（深▲セン▼）新薬研究中心有限公司 | アミド化合物、医薬組成物およびその使用 |
| MX2023009954A (es) * | 2021-02-26 | 2023-11-09 | Tyra Biosciences Inc | Compuestos de aminopirimidina y métodos de uso de estos. |
| AU2022233254A1 (en) * | 2021-03-11 | 2023-10-26 | Janssen Pharmaceutica Nv | Lorpucitinib for use in the treatment of jak mediated disorders |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| WO2025230951A1 (en) * | 2024-04-29 | 2025-11-06 | Icahn School Of Medicine At Mount Sinai | Method of treating adenoid cystic carcinoma |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ584499A (en) | 2004-03-30 | 2011-08-26 | Vertex Pharma | Azaindoles Useful as Inhibitors of Jak and Other Protein Kinases |
| GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| DK1945631T3 (da) | 2005-10-28 | 2012-10-22 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer |
| EA200870217A1 (ru) * | 2006-01-30 | 2009-02-27 | Экселиксис, Инк. | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции |
| ME00811B (me) * | 2006-12-08 | 2012-03-20 | Novartis Ag | JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE |
| JP5918693B2 (ja) * | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| AR076794A1 (es) * | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| EP2611793A1 (en) * | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | 2-cycloquinazoline derivatives and methods of use thereof |
| US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| CN103298794A (zh) * | 2010-11-09 | 2013-09-11 | 塞尔卓姆有限公司 | 作为tyk2抑制剂的吡啶化合物及其氮杂类似物 |
| CN103415515B (zh) * | 2010-11-19 | 2015-08-26 | 因塞特公司 | 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物 |
| WO2012116247A1 (en) * | 2011-02-25 | 2012-08-30 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
| PE20140832A1 (es) * | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
| PL2830662T3 (pl) | 2012-03-29 | 2019-02-28 | The Trustees Of Columbia University In The City Of New York | Sposoby leczenia zaburzeń utraty włosów |
| CN111606893B (zh) * | 2015-09-25 | 2021-05-04 | 迪哲(江苏)医药股份有限公司 | 用于抑制jak的化合物和方法 |
-
2016
- 2016-09-22 CN CN202010629290.1A patent/CN111606893B/zh active Active
- 2016-09-22 MX MX2018003590A patent/MX375724B/es active IP Right Grant
- 2016-09-22 CN CN202010629286.5A patent/CN111646980B/zh active Active
- 2016-09-22 CN CN201680055491.7A patent/CN108368091B/zh active Active
- 2016-09-22 PT PT167700319T patent/PT3353168T/pt unknown
- 2016-09-22 DK DK16770031.9T patent/DK3353168T3/da active
- 2016-09-22 BR BR112018005833-5A patent/BR112018005833B1/pt active IP Right Grant
- 2016-09-22 CN CN202010626114.2A patent/CN111848586B/zh active Active
- 2016-09-22 US US15/272,554 patent/US9714236B2/en active Active
- 2016-09-22 ES ES16770031T patent/ES2956642T3/es active Active
- 2016-09-22 JP JP2018535238A patent/JP6767491B2/ja active Active
- 2016-09-22 EP EP23150992.8A patent/EP4219482A1/en active Pending
- 2016-09-22 WO PCT/EP2016/072616 patent/WO2017050938A1/en not_active Ceased
- 2016-09-22 KR KR1020257006096A patent/KR20250035597A/ko active Pending
- 2016-09-22 AU AU2016328764A patent/AU2016328764B2/en active Active
- 2016-09-22 CA CA2995430A patent/CA2995430C/en active Active
- 2016-09-22 KR KR1020187008186A patent/KR102774784B1/ko active Active
- 2016-09-22 EP EP16770031.9A patent/EP3353168B1/en active Active
- 2016-09-22 RU RU2018112993A patent/RU2760359C2/ru active
- 2016-09-23 AR ARP160102919A patent/AR106138A1/es active IP Right Grant
- 2016-09-23 TW TW105130891A patent/TWI740843B/zh active
-
2017
- 2017-05-22 US US15/601,324 patent/US10167276B2/en active Active
-
2018
- 2018-02-06 ZA ZA2018/00782A patent/ZA201800782B/en unknown
- 2018-11-20 US US16/196,038 patent/US10654835B2/en active Active
-
2020
- 2020-04-28 US US16/860,169 patent/US11247983B2/en active Active
-
2021
- 2021-12-28 US US17/563,913 patent/US12319670B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX375724B (es) | Compuestos y métodos para la inhibición de jak. | |
| MX2020001235A (es) | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. | |
| MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
| CY1122279T1 (el) | Ενωσεις ναφθυριδινης αναστολεις κινασης jak | |
| PH12019501639B1 (en) | Jak1 selective inhibitors | |
| MX386103B (es) | Inhibidores de mcl-1 y metodos de uso de los mismos. | |
| WO2019173082A8 (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| CY1124173T1 (el) | Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| WO2014031438A3 (en) | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
| RU2018113718A (ru) | Новые соединения | |
| MX2021012096A (es) | Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo. | |
| PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| EA201792320A1 (ru) | Способ лечения рака ингибитором пути stat3 и ингибитором киназы | |
| TN2016000459A1 (en) | Cycloalkyl-linked diheterocycle derivatives. | |
| EA201792087A1 (ru) | ПРОИЗВОДНЫЕ 7-(МОРФОЛИН-4-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИМИДИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ИММУННЫХ ИЛИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ИЛИ РАКА |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |